Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

portfolio company news
Written By Megan Prock McGrath

Neumora today announced that it has entered into a venture debt facility for up to $125 million with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. Under the terms of the facility, $20 million was drawn at closing, with an additional $20 million available to be drawn at Neumora’s option by December 31, 2025. The additional $85 million will be available for drawdown at Neumora's option upon the achievement of certain milestones.

Megan Prock McGrath
Previous

Fuze Health Launches to Transform Patient Experiences and Enable Personalized Care in a Changing Healthcare Environment
Next

Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials